Literature DB >> 1815549

Anti-cell antibody in macaques.

E J Stott.   

Abstract

Mesh：

Substances：

Year:  1991        PMID： 1815549     DOI： 10.1038/353393a0

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  78 in total

1.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: reevaluation of neutralizing antibody levels elicited by a protective and a nonprotective vaccine after removal of antisubstrate cell antibodies.

Authors:  S Giannecchini; D Del Mauro; D Matteucci; M Bendinelli
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 2.  Strategies for an HIV vaccine.

Authors:  Norman L Letvin
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

3.  A gp120 HIV peptide with high similarity to HLA class II beta chains enhances PPD-specific and autoreactive T cell activation.

Authors:  O Pugliese; M Viora; B Camponeschi; P Cordiali Fei; F Caprilli; A Chersi; M Evangelista; A M Di Massimo; V Colizzi
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

4.  Neutralizing antibodies modulate replication of simian immunodeficiency virus SIVmac in primary macaque macrophages.

Authors:  M F McEntee; M C Zink; M G Anderson; H Farzadegan; R J Adams; K A Kent; E J Stott; J E Clements; O Narayan
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

5.  Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge.

Authors:  P R Johnson; D C Montefiori; S Goldstein; T E Hamm; J Zhou; S Kitov; N L Haigwood; L Misher; W T London; J L Gerin
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

6.  Studies of AIDS vaccination using an ex vivo feline immunodeficiency virus model: protection conferred by a fixed-cell vaccine against cell-free and cell-associated challenge differs in duration and is not easily boosted.

Authors:  D Matteucci; M Pistello; P Mazzetti; S Giannecchini; D Del Mauro; I Lonetti; L Zaccaro; C Pollera; S Specter; M Bendinelli
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

7.  HIV-1 vaccine development: progress and prospects.

Authors:  Anna R Thorner; Dan H Barouch
Journal:  Curr Infect Dis Rep       Date:  2007-01       Impact factor: 3.725

Review 8.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

9.  Cytoskeletal proteins bound to heat-shock protein 70 may elicit resistance to simian immunodeficiency virus infection of CD4(+) T cells.

Authors:  Lesley A Bergmeier; Kaboutar Babaahmady; Jeffrey Pido-Lopez; Kate J Heesom; Charles G Kelly; Thomas Lehner
Journal:  Immunology       Date:  2009-11-25       Impact factor: 7.397

10.  Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus.

Authors:  L O Arthur; J W Bess; R G Urban; J L Strominger; W R Morton; D L Mann; L E Henderson; R E Benveniste
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.